Premium
The treatment of hidradenitis suppurativa with the glucagon‐like peptide‐1 agonist liraglutide
Author(s) -
Jennings L.,
Nestor L.,
Molloy O.,
Hughes R.,
Moriarty B.,
Kirby B.
Publication year - 2017
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.15233
Subject(s) - liraglutide , hidradenitis suppurativa , medicine , psoriasis , agonist , metabolic syndrome , diabetes mellitus , glucagon like peptide 1 , exenatide , disease , endocrinology , dermatology , type 2 diabetes , receptor
Summary Hidradenitis suppurativa ( HS ) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The antidiabetic agents, incretins, have been used successfully to treat psoriasis – a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon‐like peptide‐1 agonist, in a patient with HS , leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS .